Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone
Drug ID BADD_D00623
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]
Marketing Status approved; investigational; vet_approved
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00292
MeSH ID D003907
PubChem ID 5743
TTD Drug ID D0IT2G
NDC Product Code 80425-0328; 0009-5019; 22552-0039; 38779-0405; 0904-7266; 55154-4901; 63187-561; 67296-1496; 70518-2998; 70868-920; 0054-4183; 0054-8176; 0054-8181; 0054-8183; 0998-0615; 55718-133; 71161-138; 79572-012; 42195-490; 45865-989; 55154-4914; 68788-8223; 70382-204; 71205-012; 42291-155; 50090-0088; 60687-718; 60687-729; 64980-509; 68788-8467; 72189-383; 55289-582; 60219-2044; 67296-0326; 0054-4179; 0054-8179; 0054-8180; 72893-015; 55718-157; 65089-0045; 42195-127; 60219-2043; 63629-7850; 70954-402; 71205-013; 0054-4181; 0054-4182; 0054-4186; 71205-703; 71879-001; 46439-8765; 82298-111; 50090-6151; 61919-827; 63187-383; 63629-4129; 63629-7806; 68788-7267; 69306-111; 69306-114; 70518-3050; 70954-404; 0054-4184; 49452-2465; 0078-0925; 0023-3348; 61919-269; 68071-2744; 68788-8293; 0054-3177; 70954-403; 0054-8175; 71335-2108; 72189-254; 51552-0430; 51927-1081; 52128-170; 42195-721; 43063-266; 48102-051; 50090-0089; 54879-003; 60219-2056; 62135-114; 68788-7142; 70954-401; 0054-8174; 72189-468; 60722-3013; 0121-1814; 42195-121; 42195-149; 42195-221; 47781-914; 47781-916; 55700-961; 69306-112; 55289-903; 63629-3742; 66993-730; 67296-1837; 68071-2321; 0054-4180; 55718-156; 57582-031; 57582-931; 42195-270; 50090-6152; 51407-361
UNII 7S5I7G3JQL
Synonyms Dexamethasone | Methylfluorprednisolone | Hexadecadrol | Decameth | Decaspray | Dexasone | Dexpak | Maxidex | Millicorten | Oradexon | Decaject | Decaject-L.A. | Decaject L.A. | Hexadrol
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 50-02-2
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Premature separation of placenta24.07.03.019; 18.02.01.0040.000145%Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.000683%
Productive cough22.02.03.0050.000509%
Pruritus23.03.12.001--
Psoriatic arthropathy23.03.14.005; 15.01.10.001; 10.02.01.0310.000436%Not Available
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.000363%Not Available
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.0020.000218%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.0010.002034%Not Available
Pulmonary haemorrhage22.12.01.009; 24.07.01.0160.000363%
Pulmonary oedema22.01.03.003; 02.05.02.003--
Punctate keratitis06.04.02.0030.000218%Not Available
Pupillary disorder17.02.11.006; 06.05.03.0080.000886%Not Available
Pyrexia08.05.02.0030.010302%
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.0290.000974%Not Available
Renal failure20.01.03.0050.002790%Not Available
Respiratory acidosis22.02.02.004; 14.01.04.0020.000872%Not Available
Respiratory arrest22.02.01.0090.000799%Not Available
Respiratory distress22.02.01.0120.002107%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.004432%
Retinal degeneration06.09.03.0020.000145%Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.001962%
Retinal disorder06.08.03.0050.000363%Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.0010.000799%Not Available
Retinal ischaemia24.04.10.005; 06.10.01.0090.000218%Not Available
Retinal oedema24.03.07.006; 06.04.06.0070.000145%Not Available
Retinal tear12.01.04.014; 06.09.03.0100.000291%
Retinal vein occlusion06.10.01.010; 24.01.07.0060.000581%Not Available
Retinopathy of prematurity12.02.02.015; 06.10.02.012; 18.04.01.004--Not Available
Schizophrenia19.03.04.001--Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene